Clinical trials: AFP Expressing Tumors
Hepatocellular Carcinoma, Liver Cancer
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Clinical study to evaluate safety and pharmacokinetics (primary objectives) and efficacy (secondary objective) of ET1402L1-CART-cells in patients with AFP+ HCC
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- NCT03349255
- Testing
- autologous ET1402L1-CART cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Aeon Therapeutics (Shanghai) Co., Ltd.
Hepatocellular Carcinoma, Liver Cancer
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
Clinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- NCT03888859
- Testing
- ET1402L1-ARTEMIS™ T cells -IV, ET1402L1-ARTEMIS™ T cells -intra-hepatic artery, ET1402L1-ARTEMIS™ T cells -Intratumoral Injections
- Where
- China
- Volunteers
- 12 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatocellular Cancer, AFP Expressing Tumors
AFPᶜ³³²T in Advanced HCC
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor.
- Trial name
- NCT03132792
- Testing
- Autologous genetically modified AFPᶜ³³²T cells
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 39 people
- Sponsor
- Adaptimmune